Form 8-K - Current report:
SEC Accession No. 0001683168-26-000217
Filing Date
2026-01-12
Accepted
2026-01-12 16:00:25
Documents
14
Period of Report
2026-01-12
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K actuate_8k.htm   iXBRL 8-K 29939
2 PRESS RELEASE OF ACTUATE THERAPEUTICS, INC. DATED JANUARY 12, 2026 actuate_ex9901.htm EX-99.1 25534
3 GRAPHIC image_004.jpg GRAPHIC 3634
  Complete submission text file 0001683168-26-000217.txt   236971

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE actu-20260112.xsd EX-101.SCH 3105
5 XBRL LABEL FILE actu-20260112_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE actu-20260112_pre.xml EX-101.PRE 22380
16 EXTRACTED XBRL INSTANCE DOCUMENT actuate_8k_htm.xml XML 3331
Mailing Address 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107
Business Address 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 847-986-4190
ACTUATE THERAPEUTICS, INC. (Filer) CIK: 0001652935 (see all company filings)

EIN.: 473044785 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42139 | Film No.: 26526664
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)